Dasiglucagon in severe hypoglycemia: a profile of its use

Declarations

Funding The preparation of this review was not supported by any external funding.

Authorship and Conflict of interest Yahiya Y. Syed is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability not applicable

Additional information about this Adis Drug Review can be found here

Abstract

Subcutaneous dasiglucagon (Zegalogue^®), a next generation glucagon analog, is a convenient and valuable addition to ready-to-use glucagon formulations for the rescue treatment of severe hypoglycemia in patients aged ≥ 6 years with diabetes. A single dose of dasiglucagon reverses insulin-induced hypoglycemia typically within 10 min in this population, without need for additional intervention. The drug is generally well tolerated, with nausea and vomiting being the most frequent adverse reactions. The overall safety profile of dasiglucagon is consistent with that expected for glucagon treatment. Dasiglucagon is available in convenient auto-injector and prefilled syringe forms that can be carried at room temperature. 

© Springer Nature Switzerland AG 2021